TrialFrontiers of medicine2022

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).

Jianhua Shi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.